Vivoryon Therapeutics N.V. operates as a clinical stage biopharmaceutical company that focuses on research, development, and commercialize small molecule-based medicines. Its pipeline products target toxic pyroglutamate-Abeta (pGlu-Abeta), which inhibits the production of pGlu-Abeta. The company’s lead product candidate is PQ912, a nanomolar QPCT inhibitor that has completed Phase IIb clinical trials for use in the treatment of Alzheimer’s disease. In addition, the company is developing a monoclonal antibody PBD-C06 is for N3pE-Abeta. Vivoryon Therapeutics N.V. has a collaboration agreement with Nordic Bioscience for the clinical development of PQ912 for Alzheimer's disease; and research collaboration with the Fraunhofer Institute for cell therapy and immunology, as well as a strategic regional licensing partnership with Simcere Pharmaceutical Group Ltd. to develop and commercialize medicines targeting the neurotoxic amyloid species N3pE (pGlu-Abeta) to treat Alzheimer's disease. The company was founded in 1997 and is based in Halle, Germany.
Metrics to compare | VVYN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipVVYNPeersSector | |
---|---|---|---|---|
P/E Ratio | −1.8x | −3.3x | −0.5x | |
PEG Ratio | −0.06 | 0.05 | 0.00 | |
Price/Book | 4.8x | 1.0x | 2.6x | |
Price / LTM Sales | - | 13.0x | 3.2x | |
Upside (Analyst Target) | - | 43.2% | 42.0% | |
Fair Value Upside | Unlock | 0.6% | 6.6% | Unlock |